CNMD / CONMED Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 CONMED CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number June 30, 2025 001-39218 CONMED CORPORATION (Exact name of the registrant as spec

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) (

CONMED Corporation Announces Second Quarter 2025 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer [email protected] CONMED Corporation Announces Second Quarter 2025 Financial Results Largo, Florida, July 30, 2025 – CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights •Sales of $342.3 million increased 3.1% year-over-year as

Martha Aronson to Step Down from CONMED Board of Directors Following Appointment as President and Chief Executive Officer of Merit Medical Systems, Inc.

Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer [email protected] Martha Aronson to Step Down from CONMED Board of Directors Following Appointment as President and Chief Executive Officer of Merit Medical Systems, Inc. Largo, Fla. – July 7, 2025 – CONMED Corporation (NYSE: CNMD) today announced that Martha Aronson will be stepping down from the company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2025 CONMED CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 ¨ Transition Report Pursuant To Section 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ¨ Transition Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-39218 (A) Full title of the plan and the add

Eighth Amended and Restated Credit Agreement, dated as of June 10, 2025, among CONMED Corporation, the foreign subsidiary borrowers from time to time party thereto, the several lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.

Exhibit 10.1 EIGHTH AMENDED AND RESTATED CREDIT AGREEMENT among CONMED CORPORATION, as Parent Borrower, The Foreign Subsidiary Borrowers From Time to Time Party Hereto, The Several Lenders from Time to Time Party Hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent Dated as of June 10, 2025 JPMORGAN CHASE BANK, N.A., BOFA SECURITIES INC., and WELLS FARGO SECURITIES, LLC, as Joint Lead Ar

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File N

Amended and Restated Guarantee and Collateral Agreement, dated as of June 10, 2025, made by CONMED Corporation and certain of its subsidiaries in favor of JPMorgan Chase Bank, N.A., as administrative agent.

Exhibit 10.2 AMENDED AND RESTATED GUARANTEE AND COLLATERAL AGREEMENT made by CONMED CORPORATION and certain of its Subsidiaries in favor of JPMORGAN CHASE BANK, N.A., as Administrative Agent Dated as of June 10, 2025 Table of Contents Page Section 1. DEFINED TERMS 1 1.1 Definitions 2 1.2 Other Definitional Provisions 5 Section 2. Guarantee 5 2.1 Guarantee 5 2.2 Right of Contribution 6 2.3 No Subro

Conflict Minerals Report as responsive to Item 1.01 and 1.02 of this Form.

Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2024 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 11311 Concept Blvd. Largo FL 33773-4908 (Address of principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2025 CONMED CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S.

As filed with the Securities and Exchange Commission on May 20, 2025.

S-8 POS As filed with the Securities and Exchange Commission on May 20, 2025. Registration No. 333-214299 Registration No. 333-228171 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-214299 Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-228171 Under the Securities Act of 1933

As filed with the Securities and Exchange Commission on May 20, 2025

As filed with the Securities and Exchange Commission on May 20, 2025 Registration No.

Filing Fee Table*

Calculation of Filing Fee Tables S-8 CONMED Corp Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.

As filed with the Securities and Exchange Commission on May 20, 2025.

S-8 POS As filed with the Securities and Exchange Commission on May 20, 2025. Registration No. 333-214299 Registration No. 333-228171 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-214299 Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-228171 Under the Securities Act of 1933

CONMED Corporation 2025 Long-Term Incentive Plan.*

EXHIBIT 4.3 CONMED CORPORATION 2025 LONG-TERM INCENTIVE PLAN 1. PURPOSE. The purpose of the 2025 Long-Term Incentive Plan of CONMED Corporation (as amended from time to time, the “Plan”) is to promote the long-term financial interests of CONMED Corporation (the “Company”), including its growth and performance, by encouraging employees of the Company and its subsidiaries and Non-Employee Directors

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number March 31, 2025 001-39218 CONMED CORPORATION (Exact name of the registrant as spe

CONMED Corporation Announces First Quarter 2025 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces First Quarter 2025 Financial Results Largo, Florida, April 30, 2025 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights · Sales of $321.3 million increased 2.9% year-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2025 CONMED CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.

CONMED Corporation Adds Mark Kaye to its Board of Directors

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Adds Mark Kaye to its Board of Directors Largo, Fla. - February 25, 2025 – CONMED Corporation (NYSE: CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. “My fellow directors and I are extremely pleased to welcom

Insider Trading Policy

EXHIBIT 19 Insider Trading Policy 1.Policy Statement This Insider Trading Policy (this “Policy”) is designed to prevent insider trading or allegations of insider trading, to protect the reputation of CONMED, its subsidiaries, and affiliated entities (collectively, the “Company”) for integrity and ethical conduct and to help the Company’s personnel avoid the severe consequences associated with viol

Subsidiaries of the Registrant.

EXHIBIT 21 CONMED Corporation Subsidiaries of the Registrant Name State or Country of Incorporation Aspen Laboratories, Inc.

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2024 Commission file number: 001-39218 CONMED CORPORATION (Exact name of registrant as specified

Description of the Common Stock of CONMED Corporation, a Delaware corporation.

Exhibit 4.1 Description of Common Stock The following is a description of the general terms, provisions and rights of the common stock, par value $0.01 ("Common Stock"), of CONMED Corporation, a Delaware corporation (the "Company," "we," "us," and "our"), related provisions of the Company’s certificate of incorporation (the “Certificate of Incorporation”) and bylaws (the “Bylaws”) and applicable D

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results Largo, Fla. - February 5, 2025 – CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights · Sales of $

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization

J.P. Morgan 43rd Annual Healthcare Conference

Exhibit 99.1 J.P. Morgan 43rd Annual Healthcare Conference Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

CNMD / CONMED Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* CONMED Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 207410101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2024 001-39218 CONMED CORPORATION (Exact name of the registrant as

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission Fil

Amendment Number 2 to Service Agreement, by and between CONMED U.K. Limited and Pat Beyer, dated October 30, 2024.

Exhibit 10.1 DATED October 30, 2024 BETWEEN CONMED U.K. LIMITED (1) PAT BEYER (2) SERVICE AGREEMENT CONTENTS 1. DEFINITIONS AND INTERPRETATION 1 2. TERM OF EMPLOYMENT 3 3. JOB TITLE AND DUTIES 3 4. EMPLOYEE WARRANTIES 5 5. PLACE OF WORK 6 6. REMUNERATION AND BENEFITS 6 7. EXPENSES 9 8. NORMAL HOURS OF WORK 10 9. HOLIDAY ENTITLEMENT 10 10. NOTIFICATION OF SICKNESS OR OTHER ABSENCE AND MEDICAL EXAMI

CONMED Corporation Announces Third Quarter 2024 Financial Results

Exhibit 99.1    NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Third Quarter 2024 Financial Results Largo, Florida, October 30, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights • Sales of $316.7 millio

Letter Agreement, by and between CONMED and Curt R. Hartman, dated October 30, 2024.

Exhibit 10.2 Martha Goldberg Aronson 11311 Concept Blvd Largo, FL 33773 October 30, 2024 Curt R. Hartman Address on file with the Company Re: Transition to Special Advisor Dear Curt: This letter (this “Letter Agreement”) confirms our recent discussions regarding your transition to a Special Advisor role with CONMED Corporation (the “Company”). On behalf of the Board of Directors of the Company (th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2024 CONMED CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization)

CONMED Corporation Announces Preliminary Third Quarter Financial Information

EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Preliminary Third Quarter Financial Information LARGO, Fla. – October 4, 2024 –As a follow up to the Current Report on Form 8-K issued by the Company on September 30, 2024, CONMED Corporation (NYSE: CNMD) announced preliminary financia

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organizati

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 CONMED CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number June 30, 2024 001-39218 CONMED CORPORATION (Exact name of the registrant as spec

Fourth Amendment, dated July 19, 2024, to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021, among CONMED Corporation, the foreign subsidiary borrowers from time to time party thereto, the several lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (Incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024).

Exhibit 10.1 FOURTH AMENDMENT FOURTH AMENDMENT, dated as of July 19, 2024 (this “Amendment”), to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among CONMED Corporation, a Delaware corporation (the “Parent Borrower”), the Foreign Subsidiary Borrowers (as defined therein) from t

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S.

CONMED Corporation Announces Second Quarter 2024 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Second Quarter 2024 Financial Results Largo, Florida, July 31, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights · Sales of $332.1 million increased 4.5% year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 ¨ Transition Report Pursuant To Section 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 OR ¨ Transition Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-39218 (A) Full title of the plan and the add

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S.

Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 11311 Concept Blvd. Largo FL 33773-4908 (Address of principal

Conflict Minerals Report as responsive to Item 1.01 and 1.02 of this Form.

Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2023 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number March 31, 2024 001-39218 CONMED CORPORATION (Exact name of the registrant as spe

Amendment Number 1 to Service Agreement, by and between CONMED U.K. Limited and Pat Beyer, dated April 24, 2024

Exhibit 10.1 CONFIDENTIAL April 24, 2024 Mr. Pat Beyer 11 River Park Drive Marlow, Buckinghamshire, England SL7 1QT Re: Amended Employment Terms Dear Pat: Please accept this letter as Amendment Number 1 (this “Amendment”) to your April 25, 2019, Service Agreement with CONMED U.K. Limited (the “Service Agreement”). This Amendment will supplement and amend your Service Agreement effective as of Apri

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 24, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S

CONMED Corporation Announces First Quarter 2024 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces First Quarter 2024 Financial Results Largo, Florida, April 24, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights · Sales of $312.3 million increased 5.7% year-

Letter Agreement, by and between CONMED and Heather Cohen, dated April 19, 2024

Exhibit 10.2 CONFIDENTIAL Curt R. Hartman 11311 Concept Blvd Largo, FL 33773 April 19, 2024 Heather L. Cohen Address on file with the Company Re: Transition to Special Advisor Dear Heather: This letter (this “Letter Agreement”) confirms our recent discussions regarding your transition to a Special Advisor role with CONMED Corporation (the “Company”). On behalf of the Board of Directors of the Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

Subsidiaries of the Registrant.

EXHIBIT 21 CONMED Corporation Subsidiaries of the Registrant Name State or Country of Incorporation Aspen Laboratories, Inc.

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2023 Commission file number: 001-39218 CONMED CORPORATION (Exact name of registrant as specified

Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation (Incorporated by reference to Exhibit 97 of the Company's Annual Report on Form 10-K for the year ended December 31, 2023)

Exhibit 97 CONMED CORPORATION POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE-BASED COMPENSATION I.

Description of the Common Stock of CONMED Corporation, a Delaware corporation.

Exhibit 4.1 Description of Common Stock The following is a description of the general terms, provisions and rights of the common stock, par value $0.01 ("Common Stock"), of CONMED Corporation, a Delaware corporation (the "Company," "we," "us," and "our"), related provisions of the Company’s certificate of incorporation (the “Certificate of Incorporation”) and bylaws (the “Bylaws”) and applicable D

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.

CNMD / CONMED Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0669-conmedcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: CONMED Corp Title of Class of Securities: Common Stock CUSIP Number: 207410101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pu

CNMD / CONMED Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* CONMED Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 207410101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

CONMED Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results Largo, Florida, January 31, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Highlights · Sales of

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 4, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2023 001-39218 CONMED CORPORATION (Exact name of the registrant as

CONMED Corporation Announces Third Quarter 2023 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Third Quarter 2023 Financial Results Largo, Florida, October 25, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights · Sales of $304.6 million increased 10.7

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2023 CONMED CORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 CONMED CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number June 30, 2023 001-39218 CONMED CORPORATION (Exact name of the registrant as spec

Amended and Restated Certificate of Incorporation of CONMED Corporation

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONMED CORPORATION June 1, 2023 CONMED Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2023 CONMED CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S.

CONMED Corporation Announces Second Quarter 2023 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Second Quarter 2023 Financial Results Largo, Florida, July 26, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights · Sales of $317.7 million increased 14.6% yea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 ¨ Transition Report Pursuant To Section 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 OR ¨ Transition Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-39218 (A) Full title of the plan and the add

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 CONMED CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 11311 Concept Blvd. Largo FL 33773-4908 (Address of principal

Conflict Minerals Report as responsive to Item 1.01 and 1.02 of this Form.

Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2022 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number March 31, 2023 001-39218 CONMED CORPORATION (Exact name of the registrant as spe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2023 CONMED CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S

CONMED Corporation Announces First Quarter 2023 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces First Quarter 2023 Financial Results Largo, Florida, April 26, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights · Sales of $295.5 million increased 21.9% year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2023 CONMED CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.

Subsidiaries of the Registrant.

EXHIBIT 21 CONMED Corporation Subsidiaries of the Registrant Name State or Country of Incorporation Aspen Laboratories, Inc.

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2022 Commission file number: 001-39218 CONMED CORPORATION (Exact name of registrant as specified

Description of the Common Stock of CONMED Corporation, a Delaware corporation.

Exhibit 4.1 Description of Common Stock The following is a description of the general terms, provisions and rights of the common stock, par value $0.01 ("Common Stock"), of CONMED Corporation, a Delaware corporation (the "Company," "we," "us," and "our"), related provisions of the Company’s certificate of incorporation (the “Certificate of Incorporation”) and bylaws (the “Bylaws”) and applicable D

CNMD / Conmed Corp / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CONMED Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 207410101 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

CNMD / Conmed Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0647-conmedcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: CONMED Corp. Title of Class of Securities: Common Stock CUSIP Number: 207410101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule p

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

CONMED Corporation Announces Fourth Quarter and Full-Year 2022 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Fourth Quarter and Full-Year 2022 Financial Results Largo, Florida, February 2, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2022. Fourth Quarter 2022 Highlights · Fourth q

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission Fi

Third Amendment, dated December 20, 2022, to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021, among CONMED Corporation, the foreign subsidiary borrowers from time to time party thereto, the several lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (Incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 27, 2022).

EX-10.1 2 d444290dex101.htm EX-10.1 Exhibit 10.1 THIRD AMENDMENT THIRD AMENDMENT, dated as of December 20, 2022 (this “Amendment”), to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among CONMED Corporation, a Delaware corporation (the “Parent Borrower”), the Foreign Subsidiary

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 CONMED CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission Fil

Letter Agreement, by and between CONMED Corporation and Daniel S. Jonas, dated December 6, 2022.

EX-10.1 Exhibit 10.1 Heather Cohen EVP Human Resources 11311 Concept Blvd Largo, FL 33773 December 6, 2022 Daniel S. Jonas, Esq. 1901 Walnut Street, Apartment 12B Rittenhouse Plaza Philadelphia, PA 19103 Re: Employment Transition and Retirement Agreement Dear Dan, This letter confirms our recent discussions regarding your continued at-will employment with CONMED Corporation (the “Company”), includ

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

Forward-Looking Information This presentation contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of t

Investor Presentation Curt R. Hartman Chair of the Board, President, and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer November 15, 2022 Exhibit 99.2 Forward-Looking Information This presentation contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are ma

CONMED Corporation Withdraws 2022 Financial Outlook due to Temporary Impact from Software Implementation; Provides 2023 Financial Outlook

Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Withdraws 2022 Financial Outlook due to Temporary Impact from Software Implementation; Provides 2023 Financial Outlook LARGO, Fla. ? November 15, 2022 ? CONMED Corporation (NYSE: CNMD) today announced that due to a temporary disruption resulting from th

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2022 001-39218 CONMED CORPORATION (Exact name of the registrant as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 CONMED CORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

CONMED Corporation Announces Third Quarter 2022 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Third Quarter 2022 Financial Results Largo, Florida, October 26, 2022 – CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights · Sales of $275.1 million increased 10.6

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.

Regulation FD Disclosure, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other Jurisdiction of Incorporation) (Commission File

CONMED Completes Acquisition of Biorez, Inc.

Exhibit 99.1 NEWS RELEASE CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Completes Acquisition of Biorez, Inc. Largo, Florida, August 9, 2022 ? CONMED Corporation (NYSE: CNMD) today announced that it has completed its previously announced acquisition of privately-held Biorez, Inc. Biorez is a medical device start-up based in New Haven, CT and is fo

CONMED Announces Definitive Agreement to Acquire Biorez, Inc.

Exhibit 99.1 NEWS RELEASE CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Announces Definitive Agreement to Acquire Biorez, Inc. ? Through this acquisition, CONMED acquires next generation bioinductive collagen scaffold technology for application in sports medicine soft tissue healing ? CONMED to host conference call today at 4:30 p.m. ET Largo, Flo

Second Amendment, dated August 1, 2022, to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021, among CONMED Corporation, the foreign subsidiary borrowers from time to time party thereto, the several lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (Incorporated by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 2, 2022).

Exhibit 10.2 SECOND AMENDMENT SECOND AMENDMENT, dated as of August 1, 2022 (this ?Amendment?), to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021 (as amended, supplemented or otherwise modified from time to time, the ?Credit Agreement?), among CONMED Corporation, a Delaware corporation (the ?Parent Borrower?), the Foreign Subsidiary Borrowers (as defined therein) from

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other Jurisdiction of Incorporation) (Commission File

Agreement and Plan of Merger, dated as of August 1, 2022, by and among CONMED Corporation, Prometheus Merger Sub, Inc., Biorez, Inc. and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative, agent and attorney-in-fact of Biorez’s securityholders (Incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 2, 2022).

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY ?[***]?, HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT AND PLAN OF MERGER by and among BIOREZ, INC., CONMED CORPORATION, PROMETHEUS MERGER SUB, INC. and SHAREHOLDER REPRESENTATIVE SERVICES LLC Dated as of August 1,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number June 30, 2022 001-39218 CONMED CORPORATION (Exact name of the registrant as spec

e 30, 2022, by and between CONMED Corporation and

Exhibit 10.1 SUPPLEMENTAL INDENTURE 2.25% Convertible Senior Notes due 2027 SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?), dated as of June 30, 2022, between CONMED Corporation, a Delaware corporation, as issuer (the ?Company?), and U.S. Bank Trust Company, National Association, a national banking association organized under the laws of the United States of America, as trustee (the ?Trust

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) (

CONMED Corporation Announces Second Quarter 2022 Financial Results

Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Second Quarter 2022 Financial Results Largo, Florida, July 27, 2022 ? CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights ? Sales of $277.2 million increa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 ¨ Transition Report Pursuant To Section 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ? Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 OR ? Transition Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-39218 (A) Full title of the plan and the add

CONMED Completes Acquisition of In2Bones Global, Inc.

Exhibit 99.1 NEWS RELEASE CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Completes Acquisition of In2Bones Global, Inc. Largo, Florida, June 13, 2022 ? CONMED Corporation (NYSE: CNMD) today announced that it has completed its previously announced acquisition of privately-held In2Bones Global Inc. Headquartered in Memphis, Tennessee, In2Bones is a g

Regulation FD Disclosure, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other Jurisdiction of Incorporation) (Commission File N

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu

Additional Note Hedge Transaction Confirmation, dated as of June 2, 2022, among CONMED Corporation, Jefferies International Limited and Jefferies LLC, as agent (Incorporated by reference to Exhibit 10.15 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.15 Jefferies International Limited 100 Bishopsgate London EC2N 4JL United Kingdom c/o Jefferies LLC, as agent for Jefferies International Limited 520 Madison Avenue New York, NY 10022 Telephone: 212-284-2300 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Call Option Transaction The purpose

Additional Note Hedge Transaction Confirmation, dated as of June 2, 2022, between CONMED Corporation and JPMorgan Chase Bank, National Association (Incorporated by reference to Exhibit 10.16 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.16 JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the call option tra

Additional Warrant Transaction Confirmation, dated as of June 2, 2022, between CONMED Corporation and JPMorgan Chase Bank, National Association (Incorporated by reference to Exhibit 10.22 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.22 JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the Warrants issued by CONMED Corp

Base Note Hedge Transaction Confirmation, dated as of June 1, 2022, between CONMED Corporation and Barclays Bank PLC, through its agent Barclays Capital Inc. (Incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

EX-10.1 4 d320648dex101.htm EX-10.1 Exhibit 10.1 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel

Base Warrant Transaction Confirmation, dated as of June 1, 2022, between CONMED Corporation and JPMorgan Chase Bank, National Association (Incorporated by reference to Exhibit 10.10 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.10 JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the Warrants issued by CONMED Corporatio

Additional Warrant Transaction Confirmation, dated as of June 2, 2022, between CONMED Corporation and Bank of America, N.A. (Incorporated by reference to Exhibit 10.20 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.20 Bank of America, N.A. One Bryant Park, 8th Fl. New York, NY 10036 Attention: Strategic Equity Solutions Group Telephone: 646-855-8900 Email: [email protected] June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Warrants The purpose of this letter agreement (this ?Confirmat

Additional Warrant Transaction Confirmation, dated as of June 2, 2022, between CONMED Corporation and Wells Fargo Bank, National Association (Incorporated by reference to Exhibit 10.24 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.24 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 From: Wells Fargo Bank, National Association (?Dealer?) 30 Hudson Yards New York, NY 10001-2170 Email: [email protected] Re: Additional Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the ter

Base Note Hedge Transaction Confirmation, dated as of June 1, 2022, among CONMED Corporation, Jefferies International Limited and Jefferies LLC, as agent (Incorporated by reference to Exhibit 10.3 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.3 Jefferies International Limited 100 Bishopsgate London EC2N 4JL United Kingdom c/o Jefferies LLC, as agent for Jefferies International Limited 520 Madison Avenue New York, NY 10022 Telephone: 212-284-2300 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Call Option Transaction The purpose of thi

Indenture, dated as of June 6, 2022, by and between CONMED Corporation and U.S. Bank Trust Company, National Association, as trustee (Incorporated by reference to Exhibit 4.1 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 4.1 CONMED CORPORATION as Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of June 6, 2022 2.25% Convertible Senior Notes due 2027 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 5 Section 1.02. References to Interest 18 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and Amou

First Amendment, dated June 6, 2022, to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021, among CONMED Corporation, the foreign subsidiary borrowers from time to time party thereto, the several lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (Incorporated by reference to Exhibit 10.25 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.25 FIRST AMENDMENT FIRST AMENDMENT, dated as of June 6, 2022 (this ?Amendment?), to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021 (as amended, supplemented or otherwise modified from time to time, the ?Credit Agreement?), among CONMED Corporation, a Delaware corporation (the ?Parent Borrower?), the Foreign Subsidiary Borrowers (as defined therein) from tim

Additional Warrant Transaction Confirmation, dated as of June 2, 2022, between CONMED Corporation and Barclays Bank PLC, through its agent Barclays Capital Inc. (Incorporated by reference to Exhibit 10.19 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.19 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Add

Additional Note Hedge Transaction Confirmation, dated as of June 2, 2022, between CONMED Corporation and Wells Fargo Bank, National Association (Incorporated by reference to Exhibit 10.18 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.18 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 From: Wells Fargo Bank, National Association (?Dealer?) 30 Hudson Yards New York, NY 10001-2170 Email: [email protected] Re: Additional Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to

Base Warrant Transaction Confirmation, dated as of June 1, 2022, between CONMED Corporation and Nomura Global Financial Products Inc., through its agent Nomura Securities International, Inc. (Incorporated by reference to Exhibit 10.11 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.11 Nomura Global Financial Products Inc. c/o Nomura Securities International, Inc. Worldwide Plaza 309 West 49th Street New York, NY 10019 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of

Additional Note Hedge Transaction Confirmation, dated as of June 2, 2022, between CONMED Corporation and Barclays Bank PLC, through its agent Barclays Capital Inc. (Incorporated by reference to Exhibit 10.13 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.13 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Add

Additional Hedge Transaction Confirmation, dated as of June 2, 2022, between CONMED Corporation and Nomura Global Financial Products Inc., through its agent Nomura Securities International, Inc. (Incorporated by reference to Exhibit 10.17 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.17 Nomura Global Financial Products Inc. c/o Nomura Securities International, Inc. Worldwide Plaza 309 West 49th Street New York, NY 10019 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm the ter

Base Note Hedge Transaction Confirmation, dated as of June 1, 2022, between CONMED Corporation and Nomura Global Financial Products Inc., through its agent Nomura Securities International, Inc. (Incorporated by reference to Exhibit 10.5 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.5 Nomura Global Financial Products Inc. c/o Nomura Securities International, Inc. Worldwide Plaza 309 West 49th Street New York, NY 10019 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and

Additional Warrant Transaction Confirmation, dated as of June 2, 2022, between CONMED Corporation and Nomura Global Financial Products Inc., through its agent Nomura Securities International, Inc. (Incorporated by reference to Exhibit 10.23 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.23 Nomura Global Financial Products Inc. c/o Nomura Securities International, Inc. Worldwide Plaza 309 West 49th Street New York, NY 10019 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditio

Base Note Hedge Transaction Confirmation, dated as of June 1, 2022, between CONMED Corporation and Bank of America, N.A. (Incorporated by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.2 Bank of America, N.A. One Bryant Park, 8th Fl. New York, NY 10036 Attention: Strategic Equity Solutions Group Telephone: 646-855-8900 Email: [email protected] June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Call Option Transaction The purpose of this letter agreement (this ?C

Base Warrant Transaction Confirmation, dated as of June 1, 2022, between CONMED Corporation and Bank of America, N.A. (Incorporated by reference to Exhibit 10.8 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

EX-10.8 11 d320648dex108.htm EX-10.8 Exhibit 10.8 Bank of America, N.A. One Bryant Park, 8th Fl. New York, NY 10036 Attention: Strategic Equity Solutions Group Telephone: 646-855-8900 Email: [email protected] June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Warrants The purpose of this let

Additional Note Hedge Transaction Confirmation, dated as of June 2, 2022, between CONMED Corporation and Bank of America, N.A. (Incorporated by reference to Exhibit 10.14 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.14 Bank of America, N.A. One Bryant Park, 8th Fl. New York, NY 10036 Attention: Strategic Equity Solutions Group Telephone: 646-855-8900 Email: [email protected] June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Call Option Transaction The purpose of this letter agreement (

Additional Warrant Transaction Confirmation, dated as of June 2, 2022, among CONMED Corporation, Jefferies International Limited and Jefferies LLC, as agent (Incorporated by reference to Exhibit 10.21 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.21 Jefferies International Limited 100 Bishopsgate London EC2N 4JL United Kingdom c/o Jefferies LLC, as agent for Jefferies International Limited 520 Madison Avenue New York, NY 10022 Telephone: 212-284-2300 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Warrants The purpose of this letter

Base Note Hedge Transaction Confirmation, dated as of June 1, 2022, between CONMED Corporation and JPMorgan Chase Bank, National Association (Incorporated by reference to Exhibit 10.4 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.4 JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the call option transactio

Base Note Hedge Transaction Confirmation, dated as of June 1, 2022, between CONMED Corporation and Wells Fargo Bank, National Association (Incorporated by reference to Exhibit 10.6 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.6 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 From: Wells Fargo Bank, National Association (?Dealer?) 30 Hudson Yards New York, NY 10001-2170 Email: [email protected] Re: Base Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm

Base Warrant Transaction Confirmation, dated as of June 1, 2022, among CONMED Corporation, Jefferies International Limited and Jefferies LLC, as agent (Incorporated by reference to Exhibit 10.9 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.9 Jefferies International Limited 100 Bishopsgate London EC2N 4JL United Kingdom c/o Jefferies LLC, as agent for Jefferies International Limited 520 Madison Avenue New York, NY 10022 Telephone: 212-284-2300 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Warrants The purpose of this letter agreem

Base Warrant Transaction Confirmation, dated as of June 1, 2022, between CONMED Corporation and Barclays Bank PLC, through its agent Barclays Capital Inc. (Incorporated by reference to Exhibit 10.7 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.7 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base

Base Warrant Transaction Confirmation, dated as of June 1, 2022, between CONMED Corporation and Wells Fargo Bank, National Association (Incorporated by reference to Exhibit 10.12 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 10.12 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 From: Wells Fargo Bank, National Association (?Dealer?) 30 Hudson Yards New York, NY 10001-2170 Email: [email protected] Re: Base Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and

Supplemental Indenture, dated as of June 6, 2022, to the Indenture, dated January 29, 2019, by and between CONMED Corporation and U.S. Bank Trust Company, National Association, as successor to MUFG Union Bank, N.A. as trustee (Incorporated by reference to Exhibit 4.2 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 7, 2022).

Exhibit 4.2 SUPPLEMENTAL INDENTURE 2.625% Convertible Senior Notes due 2024 SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?), dated as of June 6, 2022, between CONMED Corporation, a Delaware corporation, as issuer (the ?Company?), and U.S. Bank Trust Company, National Association, as successor to MUFG Union Bank, N.A., a national banking association organized under the laws of the United Sta

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu

CONMED Corporation Announces Pricing of Upsized $700 Million Offering of Convertible Senior Notes

Exhibit 99.1 CONFIDENTIAL NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 727-241-2975 [email protected] CONMED Corporation Announces Pricing of Upsized $700 Million Offering of Convertible Senior Notes Largo, Florida, June 1, 2022 ? CONMED Corporation (NYSE: CNMD) today announced the pricing of $700 million aggregate principal amount of 2.25% convertible senior no

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu

CONMED Corporation Announces Private Offering of $600 Million of Convertible Senior Notes

EX-99.1 2 d355803dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Private Offering of $600 Million of Convertible Senior Notes Largo, Florida, May 31, 2022 – CONMED Corporation (NYSE: CNMD) today announced that it intends to offer, subject to market conditions and other facto

Conflict Minerals Report as responsive to Item 1.01 and 1.02 of this Form.

Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2021 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 11311 Concept Blvd. Largo FL 33773-4908 (Address of principal

Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number March 31, 2022 001-39218 CONMED CORPORATION (Exact name of the registrant as spe

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 (May 4, 2022) CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other Jurisdiction of Incorporation) (Commi

Agreement and Plan of Merger, dated as of May 4, 2022, by and among CONMED Corporation, Odyssey Merger Sub, Inc., In2Bones Global, Inc. and Sheryl Moroschak, solely in her capacity as representative of In2Bones’ equity holders (Incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2022).

EX-10.1 2 d664412dex101.htm EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY “[***]”, HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT AND PLAN OF MERGER by and among IN2BONES GLOBAL, INC., CONMED CORPORATION, ODYSSEY MERGER SUB, INC. and SHERYL MOROSCHAK Da

CONMED Announces Definitive Agreement to Acquire In2Bones Global, Inc.

EX-99.2 3 d351635dex992.htm EX-99.2 Exhibit 99.2 NEWS RELEASE CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Announces Definitive Agreement to Acquire In2Bones Global, Inc. Largo, Florida, May 4, 2022 – CONMED Corporation (NYSE: CNMD) today announced a definitive agreement to acquire privately-held In2Bones Global, Inc. (In2Bones), on a cash-free,

CONMED Corporation Announces First Quarter 2022 Financial Results

Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces First Quarter 2022 Financial Results Largo, Florida, May 4, 2022 ? CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights ? Sales of $242.3 million increased

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File N

Letter Agreement, by and between CONMED Corporation and Jed Kennedy, dated March 5, 2022.

Exhibit 10.1 Heather Cohen EVP Human Resources 11311 Concept Blvd Largo, FL 33773 EXECUTION VERSION March 5, 2022 John (Jed) E. Kennedy 150 Belmont Avenue Lowell, MA 01852 Re: Group EVP, AET, QA/RA, Dist, CS Transition Dear Jed: This letter confirms our recent discussions regarding your continued employment as a Special Advisor of CONMED Corporation (the ?Company?) and your planned retirement. On

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2021 Commission file number: 001-39218 CONMED CORPORATION (Exact name of registrant as specified

Subsidiaries of the Registrant.

EXHIBIT 21 CONMED Corporation Subsidiaries of the Registrant Name State or Country of Incorporation Aspen Laboratories, Inc.

Description of the Common Stock of CONMED Corporation, a Delaware corporation.

Exhibit 4.1 Description of Common Stock The following is a description of the general terms, provisions and rights of the common stock, par value $0.01 ("Common Stock"), of CONMED Corporation, a Delaware corporation (the "Company," "we," "us," and "our"), related provisions of the Company?s certificate of incorporation (the ?Certificate of Incorporation?) and bylaws (the ?Bylaws?) and applicable D

CNMD / Conmed Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: CONMED Corp. Title of Class of Securities: Common Stock CUSIP Number: 207410101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

CONMED Corporation Announces Fourth Quarter and Full-Year 2021 Financial Results

EX-99.1 2 ex99-1.htm EX-99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Fourth Quarter and Full-Year 2021 Financial Results Largo, Florida, January 26, 2022 – CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quart

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 26, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2021 001-39218 CONMED CORPORATION (Exact name of the registrant as

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 27, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

CONMED Corporation Announces Third Quarter Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Third Quarter Financial Results Largo, Florida, October 27, 2021 ? CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Highlights ? Sales of $248.8 million increased 4.6% year

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number June 30, 2021 001-39218 CONMED CORPORATION (Exact name of the registrant as spec

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S.

CONMED Corporation Announces Second Quarter Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Second Quarter Financial Results Largo, Florida, July 28, 2021 ? CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Highlights ? Sales of $255.2 million increased 61.7% year ove

Fifth Amendment to Guarantee and Collateral Agreement, dated as of July 16, 2021, made by CONMED Corporation and certain of its subsidiaries in favor of JPMorgan Chase Bank, N.A., as administrative agent.

Exhibit 10.2 FIFTH AMENDMENT TO GUARANTEE AND COLLATERAL AGREEMENT FIFTH AMENDMENT, dated as of July 16, 2021 (this ?Amendment?), to the Guarantee and Collateral Agreement, dated as of August 28, 2002 (as amended, modified or supplemented from time to time, the ?Guarantee and Collateral Agreement?), made by each of the signatories thereto (together with any other entity that may become a party the

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File N

Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021, among CONMED Corporation, the foreign subsidiary borrowers from time to time party thereto, the several lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.

Exhibit 10.1 SEVENTH AMENDED AND RESTATED CREDIT AGREEMENT among CONMED CORPORATION, as Parent Borrower, The Foreign Subsidiary Borrowers From Time to Time Parties Hereto, The Several Lenders from Time to Time Parties Hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent Dated as of July 16, 2021 JPMORGAN CHASE BANK, N.A., BOFA SECURITIES INC., and WELLS FARGO SECURITIES, LLC, as Joint Le

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 ¨ Transition Report Pursuant To Section 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ? Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 OR ? Transition Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-39218 (A) Full title of the plan and the add

Conflict Minerals Report as responsive to Item 1.01 and 1.02 of this Form.

Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2020 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 11311 Concept Blvd. Largo FL 33773-4908 (Address of principal

Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number March 31, 2021 001-39218 CONMED CORPORATION (Exact name of the registrant as spe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S

CONMED Corporation Announces First Quarter Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

- DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.

Annual Report - 10-K

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2020 Commission file number: 001-39218 CONMED CORPORATION (Exact name of registrant as specified

Description of the Common Stock of CONMED Corporation, a Delaware corporation.

Exhibit 4.1 Description of Common Stock The following is a description of the general terms, provisions and rights of the common stock, par value $0.01 ("Common Stock"), of CONMED Corporation, a Delaware corporation (the "Company," "we," "us," and "our"), related provisions of the Company?s certificate of incorporation (the ?Certificate of Incorporation?) and bylaws (the ?Bylaws?) and applicable D

Amendment Number 1 to Employment Agreement between CONMED Corporation and Curt R. Hartman dated December 28, 2020 (Incorporated by reference to Exhibit 10.2 of the Company's Annual Report on Form 10-K for the year ended December 31, 2020).

Exhibit 10.2 Martha Goldberg Aronson Lead Independent Director of the Board of Directors CONMED Corporation 525 French Road Utica, NY 13502 December 2020 Mr. Curt R. Hartman [Address on File] Re: Amended Employment Terms Dear Curt: Please accept this letter as Amendment Number 1 to your November 9, 2014 Letter Agreement with CONMED Corporation (?Amendment?). This Amendment will supplement and amen

Subsidiaries of the Registrant.

EXHIBIT 21 CONMED Corporation Subsidiaries of the Registrant Name State or Country of Incorporation Aspen Laboratories, Inc.

Amendment Number 1 to Offer Letter from CONMED Corporation to Todd W. Garner dated December 28, 2020 (Incorporated by reference to Exhibit 10.27 on the Company's Annual Report on Form 10-K for the year ended December 31, 2020).

Exhibit 10.27 Heather L. Cohen EVP Human Resources Conmed Corporation 525 French Road Utica, New York 13502 Direct Dial (315) 624-3215 December 28, 2020 Mr. Todd W. Garner [Address on File] Re: Amended Employment Terms Dear Todd: Please accept this letter as Amendment Number 1 to your January 2, 2018 Letter Agreement with CONMED Corporation (?Amendment?). This Amendment will supplement and amend y

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* CONMED Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 207410101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: CONMED Corp. Title of Class of Securities: Common Stock CUSIP Number: 207410101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 27, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

CONMED Corporation Announces Fourth Quarter and Full-Year 2020 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.

Third Amendment, dated November 20, 2020, to the Sixth Amendment and Restated Credit Agreement, dated February 7, 2019, among CONMED Corporation, the foreign subsidiary borrowers from time to time party thereto, the several lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.

EX-10.1 Exhibit 10.1 EXECUTION VERSION THIRD AMENDMENT THIRD AMENDMENT, dated as of November 20, 2020 (this “Amendment”), to the Sixth Amended and Restated Credit Agreement, dated as of February 7, 2019 (as amended by the First Amendment, dated as of March 13, 2020, the Second Amendment, dated as of April 17, 2020, and as further amended, supplemented or otherwise modified from time to time prior

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2020 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission Fi

Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 13, 2020 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2020 001-39218 CONMED CORPORATION (Exact name of the registrant as

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 28, 2020 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R

CONMED Corporation Announces Third Quarter 2020 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2020 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission F

Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2020 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number June 30, 2020 001-39218 CONMED CORPORATION (Exact name of the registrant as spec

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2020 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S.

CONMED Corporation Announces Second Quarter 2020 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.

- 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 OR ¨ Transition Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-39218 (A) Full title of the plan and the add

- SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 525 French Road Utica, New York 13502 (Address of principal e

Conflict Minerals Report as responsive to Item 1.01 and 1.02 of this Form.

Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2019 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on June 08, 2020, pursuant to the provisions of Rule 12d2-2 (a).

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

Description of the Common Stock of CONMED Corporation, a Delaware corporation.

EX-4.1 Exhibit 4.1 Description of Common Stock The following is a description of the general terms, provisions and rights of the common stock, par value $0.01 (“Common Stock”), of CONMED Corporation, a Delaware corporation (the “Company,” “we,” “us,” and “our”), related provisions of the Company’s certificate of incorporation (the “Certificate of Incorporation”) and bylaws (the “Bylaws”) and appli

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

Changes in Control of Registrant, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

Agreement and Plan of Merger, dated May 21, 2020, by and between CONMED Corporation, a New York corporation, and CONMED Corporation, a Delaware corporation (Incorporated by reference to Exhibit 2.1 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 22, 2020).

EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER THIS AGREEMENT AND PLAN OF MERGER (this “Merger Agreement”), dated as of May 21, 2020, is by and between CONMED Corporation, a New York corporation (“Parent”), and CONMED Corporation, a Delaware corporation (“Subsidiary”), pursuant to Article 9 of the Business Corporation Law of the State of New York (the “NYBCL”) and Subchapter IX of the Delaware Ge

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

Certificate of Incorporation of CONMED Corporation, a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed on May 22, 2020).

EX-3.1 Exhibit 3.1 EXECUTION VERSION CERTIFICATE OF INCORPORATION OF CONMED CORPORATION FIRST. The name of the corporation is CONMED Corporation (the “Corporation”). SECOND. The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware. THIRD. The registered office of the Corporation in t

By-laws of CONMED Corporation, a Delaware corporation (incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K, filed on May 22, 2020).

EX-3.2 Exhibit 3.2 BY-LAWS OF CONMED CORPORATION Effective April 16, 2020 ARTICLE I Stockholders Section 1.1. Annual Meeting. A meeting of stockholders shall be held annually for the election of directors and the transaction of other business on such date, time and place either within or without the State of Delaware, or may not be held at any place, but may instead be held solely by means of remo

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on May 22, 2020 Registration No.

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number March 31, 2020 001-39218 CONMED CORPORATION (Exact name of the registrant as spe

First Amendment, dated as of March 13, 2020, to the Sixth Amended and Restated Credit Agreement, dated as of February 7, 2019.

Exhibit 10.1 FIRST AMENDMENT FIRST AMENDMENT, dated as of March 13, 2020 (this “Amendment”), to the Sixth Amended and Restated Credit Agreement, dated as of February 7, 2019 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among CONMED Corporation, a New York corporation (the “Parent Borrower”), the Foreign Subsidiary Borrowers (as defined therein) from t

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2020 CONMED CORPORATION (Exact name of registrant as specified in its charter) New York 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization)

CONMED Corporation Announces First Quarter 2020 Financial Results

NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.

CONMED Corporation Announces Amendment to its Existing Credit Agreement

EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 [email protected] CONMED Corporation Announces Amendment to its Existing Credit Agreement Utica, New York, April 20, 2020 – CONMED Corporation (NYSE: CNMD) today announced an amendment to its existing credit agreement, including adjustments to, and suspension of, certain debt covenant

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2020 CONMED CORPORATION (Exact name of registrant as specified in its charter) New York 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File

Second Amendment, dated April 17, 2020, to the Sixth Amendment and Restated Credit Agreement, dated February 7, 2019, among CONMED Corporation, the foreign subsidiary borrowers from time to time party thereto, the several lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.

EX-10.1 Exhibit No. 10.1 EXECUTION VERSION SECOND AMENDMENT SECOND AMENDMENT, dated as of April 17, 2020 (this “Amendment”), to the Sixth Amended and Restated Credit Agreement, dated as of February 7, 2019 (as amended by the First Amendment, dated as of March 13, 2020, and as further amended, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”), am

Amended and Restated 2020 Non-Employee Director Equity Compensation Plan of CONMED Corporation (incorporated by reference to Exhibit D of the Registrant’s Proxy Statement on Schedule 14A filed on April 10, 2020).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State